Previous 10 | Next 10 |
-Positive topline results from COMP360’s Phase 2b study- -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4- -Continued progress across 11 therapeutic programs, including initiation of Perception’s Phase...
Mynaric (MYNA) soared more than 30% intraday Friday following a U.S. IPO for the German laser-communications firm, which enjoys backing from mega-investor Christian Angermayer, founder of legal-hallucinogens firm Atai Life Sciences (NASDAQ:ATAI). MYNA rose to as high as $22 per American Depos...
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15,...
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investo...
Palm Beach, FL –November 4, 2021 – FinancialNewsMedia.com News Commentary – The pace of society’s change in attitude to the use of psychedelics has been amazing. It has gone from a “Born To Be Wild”, hippie counter-culture illegal drug...
It’s been more than 18 months since Fortune magazine declared “ psychedelic drugs may revolutionize mental healthcare. ” Fortune pointed out how “Silicon Valley legends” and “billionaire financiers” were the main drivers of a ...
atai Life Sciences' (ATAI +0.4%) RL-007 for cognitive impairment associated with schizophrenia demonstrated potential pro-cognitive effects in a cohort in a phase 2a study. As a result, atai will commit additional funding to the program to accelerate clinical development. In addition, there w...
NetworkNewsWire Editorial Coverage : There isn’t a cigarette smoker in the world who doesn’t know smoking is bad for them. The problems are that nicotine is one of the most highly addictive substances in the world, and for the nearly 70% of 34.1 million Americans who want ...
NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai") today announced that it has observed encouraging interim data from the first 8-patient cohort of its Phase 2a trial, demonstrating potential pro-cognitive effects of its comp...
Bad news for Apple and Amazon turned into good news for Microsoft (NASDAQ:MSFT) on Friday. While two of the software giant's megacap rivals suffered earnings-inspired declines, MSFT rose to a new 52-week high and took the crown as the world's largest company by market cap. Want to hear someth...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...